专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006072589A3 DISUBSTITUTED UREAS AS KINASE INHIBITORS 审中-公开
标题翻译：作为激酶抑制剂的消除性尿路炎
公开(公告)号：WO2006072589A3
公开(公告)日：2006-10-12
申请号：PCT/EP2006000098
申请日：2006-01-09
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , FURET PASCAL , MARTINY-BARON GEORG , MCCARTHY CLIVE , RASETTI VITTORIO , VAUPEL ANDREA
发明人： FURET PASCAL , MARTINY-BARON GEORG , MCCARTHY CLIVE , RASETTI VITTORIO , VAUPEL ANDREA
IPC分类号： C07D403/12 , A61K31/496 , A61P35/00
CPC分类号： C07D403/12 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/14
摘要： The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds.
摘要翻译：本发明涉及式（I）化合物，其作为激酶抑制剂的用途，包含所述化合物的新药物制剂，用于诊断或治疗温血动物，特别是人的所述化合物，其用于治疗疾病或用于制造可用于治疗对激酶活性调节作出反应的疾病的药物制剂，包括将所述化合物施用于温血动物，特别是人的治疗方法，以及所述化合物的制备方法。

2. 发明申请

WO2006079539A3 USE OF PYRIMIDYLAMINOBENZAMIDES FOR THE TREATMENT OF DISEASES THAT RESPOND TO MODULATION OF TIE-2 KINASE ACTIVITY 审中-公开
标题翻译：用于治疗针对TIE-2激酶活性调节的疾病的吡咯烷亚胺苯甲酸酯的应用
公开(公告)号：WO2006079539A3
公开(公告)日：2007-11-29
申请号：PCT/EP2006000686
申请日：2006-01-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12 , A61P35/00
CPC分类号： A61K31/506
摘要： The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia, myelodysplastic syndromes or pulmonary hypertension, and to a method of treating diseases that respond to modulation of kinase activity, especially tie-2 kinase activity.
摘要翻译：本发明涉及嘧啶氨基苯甲酰胺化合物在制备用于治疗对激酶调节，特别是tie-2激酶，特别是用于治疗和/或预防性治疗白血病，骨髓增生异常综合征的活性的疾病的药物中的用途或肺动脉高压，以及治疗对激酶活性调节，特别是tie-2激酶活性作出反应的疾病的方法。

3. 发明专利

AT525073T 未知
公开(公告)号：AT525073T
公开(公告)日：2011-10-15
申请号：AT06706432
申请日：2006-01-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12
摘要： The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia, myelodysplastic syndromes or pulmonary hypertension, and to a method of treating diseases that respond to modulation of kinase activity, especially tie-2 kinase activity.

4. 发明专利

ES2373912T3 USO DE PIRIMIDILAMINOBENZAMIDAS PARA EL TRATAMIENTO DE ENFERMEDADES QUE RESPONDEN A LA MODULACION DE LA ACTIVIDAD DE QUINASA TIE-2. 未知
公开(公告)号：ES2373912T3
公开(公告)日：2012-02-10
申请号：ES06706432
申请日：2006-01-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12
摘要： Uso de un compuesto de pirimidilaminobenzamida de fórmula I, o un N-óxido o una sal farmacéuticamente aceptable del mismo, en el que la pirimidilaminobenzamida de fórmula I tiene la siguiente estructura: en la que R1 representa hidrógeno, alquilo inferior, alcoxi(inferior)-alquilo(inferior), aciloxi-alquilo(inferior), carboxialquilo(inferior), alcoxi(inferior)-carbonil-alquilo(inferior) o fenil-alquilo(inferior); R2 representa hidrógeno, alquilo inferior, opcionalmente sustituido con uno o más radicales R3 idénticos o diferentes, cicloalquilo, benzcicloalquilo, heterociclilo, un grupo arilo, o un grupo heteroarilo mono- o bicíclico que comprende cero, uno, dos o tres átomos de nitrógeno de anillo y cero o un átomo de oxígeno y cero o un átomo de azufre, grupos que en cada caso no están sustituidos o están mono- o polisustituidos; y R3 representa hidroxi, alcoxi inferior, aciloxi, carboxi, alcoxi(inferior)-carbonilo, carbamoílo, carbamoílo Nmono- o N,N-disustituido, amino, amino mono- o disustituido, cicloalquilo, heterociclilo, un grupo arilo, o un grupo heteroarilo mono- o bicíclico que comprende cero, uno, dos o tres átomos de nitrógeno de anillo y cero o un átomo de oxígeno y cero o un átomo de azufre, grupos que en cada caso no están sustituidos o están mono- o polisustituidos; o en la que R1 y R2 juntos representan alquileno con cuatro, cinco o seis átomos de carbono opcionalmente mono- o disustituidos con alquilo inferior, cicloalquilo, heterociclilo, fenilo, hidroxi, alcoxi inferior, amino, amino mono- o disustituido, oxo, piridilo, pirazinilo o pirimidinilo; benzalquileno con cuatro o cinco átomos de carbono; oxaalquileno con un oxígeno y tres o cuatro átomos de carbono; o azaalquileno con un nitrógeno y tres o cuatro átomos de carbono en el que el nitrógeno no está sustituido o está sustituido con alquilo inferior, fenilalquilo(inferior), alcoxi(inferior)-carbonil-alquilo(inferior), carboxi-alquilo(inferior), carbamoil-alquilo(inferior), carbamoil(N-mono- o N,N-disustituido)-alquilo(inferior), cicloalquilo, alcoxi(inferior)-carbonilo, carboxi, fenilo, fenilo sustituido, piridinilo, pirimidinilo, o pirazinilo; R4 representa hidrógeno, alquilo inferior o halógeno; y el sufijo "inferior" indica un radical que tiene hasta e incluyendo un máximo de 7 átomos de carbono, siendo los radicales en cuestión bien lineales o bien ramificados con ramificación simple o múltiple, para la fabricación de una composición farmacéutica para el tratamiento de una enfermedad que depende de la actividad de una proteína quinasa, enfermedad que es hipertensión pulmonar.

5. 发明专利

JP2013213042A USE OF PYRIMIDYLAMINOBENZAMIDES FOR TREATMENT OF DISEASES THAT RESPOND TO MODULATION OF Tie-2 KINASE ACTIVITY 审中-公开
标题翻译：用于治疗针对Tie-2激酶活性调节的疾病的吡嗪酰胺苯并噻嗪的应用
公开(公告)号：JP2013213042A
公开(公告)日：2013-10-17
申请号：JP2013140891
申请日：2013-07-04
申请人： Novartis Ag , ノバルティスアーゲー
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12 , A61P11/00 , A61P35/02 , A61P43/00
CPC分类号： A61K31/506
摘要： PROBLEM TO BE SOLVED: To provide a use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase activity, especially Tie-2 kinase activity, and to provide a method of treating diseases that respond to modulation of kinase activity, especially tie-2 kinase activity, especially for the curative and/or prophylactic treatment of leukemia and myelodysplastic syndromes.SOLUTION: Pyrimidylaminobenzamide compounds treat diseases that respond to modulation of kinase activity, especially Tie-2 kinase activity, especially for the curative and/or prophylactic treatment of leukemia and myelodysplastic syndromes.
摘要翻译：要解决的问题：提供嘧啶氨基苯甲酰胺化合物用于制备用于治疗对调节激酶活性，特别是Tie-2激酶活性的疾病的药物的用途，以及提供治疗对调节作用的疾病的方法特别是用于白血病和骨髓增生异常综合征的治疗和/或预防性治疗的激酶活性，特别是tie-2激酶活性。解决方案：嘧啶氨基苯甲酰胺化合物治疗对激酶活性调节，特别是Tie-2激酶活性的调节的疾病，特别是对于治疗和/或预防性治疗白血病和骨髓增生异常综合征。

6. 发明专利

JP2013189443A Tyrosine kinase inhibitor 审中-公开
标题翻译：酪氨酸激酶抑制剂
公开(公告)号：JP2013189443A
公开(公告)日：2013-09-26
申请号：JP2013096740
申请日：2013-05-02
申请人： Novartis Ag , ノバルティスアーゲー
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P35/00 , A61P35/04 , A61P43/00 , C07D401/14
CPC分类号： A61K31/506
摘要： PROBLEM TO BE SOLVED: To provide a new chemical compound having beneficial characteristics, which is useful for treatment of proliferative diseases such as a tumor disease.SOLUTION: This invention relates to the use of a pyrimidylaminobenzamide compound for the production of a medicine for curative and/or preventive treatments of such diseases as proliferative disorders that respond to ephrin receptor kinase, especially to the adjustment of EphB4 activity, and relates to a treatment method for such diseases that respond to kinase activity, especially to ephrin receptor kinase activity.
摘要翻译：要解决的问题：提供具有有益特性的新化合物，其可用于治疗肿瘤疾病等增殖性疾病。解决方案：本发明涉及嘧啶氨基苯甲酰胺化合物在制备治疗和/或治疗药物中的用途。 /或预防性治疗诸如对ephrin受体激酶有响应的增殖性疾病，特别是对EphB4活性的调节的疾病的治疗，以及涉及对激酶活性，特别是对ephrin受体激酶活性有响应的疾病的治疗方法。

7. 发明专利

PT1843771E USO DE PIRIMIDILAMINOBENZAMIDAS PARA O TRATAMENTO DE DOENÇAS QUE RESPONDEM À MODULAÇÃO DA ATIVIDADE DA CINASE TIE-2 未知
公开(公告)号：PT1843771E
公开(公告)日：2011-12-02
申请号：PT06706432
申请日：2006-01-26
申请人： NOVARTIS AG
发明人： MANLEY PAUL W , MESTAN JUERGEN , MARTINY-BARON GEORG
IPC分类号： A61K31/506 , A61P9/12

8. 发明专利

BRPI0613870A2 未知
公开(公告)号：BRPI0613870A2
公开(公告)日：2011-02-15
申请号：BRPI0613870
申请日：2006-07-19
申请人： NOVARTIS AG
发明人： IMBACH PATRICIA , FURET PASCAL , MARTINY-BARON GEORG
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
摘要： The invention relates to pyrazolo[1,5a]pyrimidin-7-yl amine derivatives of formula (I) and salts thereof, their use in the treatment of protein kinase dependent diseases.

9. 发明专利

CY1112568T1 ΧΡΗΣΗ ΤΩΝ ΠΥΡΙΜΙΔΥΛΑΜΙΝΟΒΕΝΖΑΜΙΔΩΝ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΩΝ ΝΟΣΩΝ ΠΟΥ ΑΝΤΑΠΟΚΡΙΝΟΝΤΑΙ ΣΤΗΝ ΡΥΘΜΙΣΗ ΤΗΣ ΔΡΑΣΗΣ ΤΗΣ ΤΙΕ-2 ΚΙΝΑΣΗΣ 未知
公开(公告)号：CY1112568T1
公开(公告)日：2016-02-10
申请号：CY111101146
申请日：2011-11-24
申请人： NOVARTIS AG
发明人： MANLEY PAUL W , MARTINY-BARON GEORG , MESTAN JUERGEN
IPC分类号： A61K31/506 , A61P9/12
摘要： Ηπαρούσαεφεύρεσηαναφέρεταιστηχρήσητωνενώσεωνπυριμιδυλαμινοβενζαμίδηςγιατηνπαρασκευήενόςφαρμάκουγιατηθεραπείατωννόσωνπουανταποκρίνονταιστηρύθμισητηςδράσηςκινάσης, συγκεκριμένατηςκινάσης tie-2, συγκεκριμέναγιατηνθεραπευτικήκαι/ήπροφυλακτικήαντιμετώπισητηςλευχαιμίας, τωνμυελοδυσπλαστικώνσυνδρόμωνή τηςπνευμονικήςυπέρτασηςκαισεμιαμέθοδοθεραπείαςτωννόσωνπουανταποκρίνονταιστηνρύθμισητηςδράσηςτηςκινάσης, συγκεκριμένατηςδράσηςτηςκινάσης tie-2.

10. 发明专利

BRPI0606707A2 未知
公开(公告)号：BRPI0606707A2
公开(公告)日：2009-07-07
申请号：BRPI0606707
申请日：2006-01-09
申请人： NOVARTIS AG
发明人： FURET PASCAL , MARTINY-BARON GEORG , MCCARTHY CLIVE , RASETTI VITTORIO , VAUPEL ANDREA
IPC分类号： C07D403/12 , A61K31/496 , A61P35/00
摘要： The invention relates to compounds of the formula (I), their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm-blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式